期刊文献+

Frat1过表达与非小细胞肺癌的不良预后相关

Correlations of Frat1 with poor prognosis of non-small cell lung cancer
原文传递
导出
摘要 目的 Frat1蛋白在食管癌、卵巢癌、中枢神经系统肿瘤中有异常表达,但是在非小细胞肺癌(NSCLC)组织中的表达情况研究甚少,其表达情况与患者预后之间是否存在相关性等尚不清楚。方法用免疫组化SP法对100例原发性NSCLC患者手术标本中Frat1的表达进行检测。结果 Frat1蛋白在肺癌组织中的表达明显增强,Frat1的阳性表达与分化程度(P=0.022)、淋巴结转移(P=0.016)和TNM分期正相关(P=0.011),并且Frat1阳性表达患者的术后生存时间(41.651±4.445个月)明显低于阴性者(74.222±6.844个月,P=0.035)。结论 Frat1在NSCLC中过表达,与肺癌的侵袭和转移等恶性表型有关,Frat1的异常表达提示NSCLC患者的不良预后。 Objective As a positive regulator of the Wnt signal pathway,frequently rearranged in advanced T-cell lymphomas(Frat1) overexpressed in some human tumors,but the role of Frat1 in non-small cell lung cancer(NSCLC) is not clear,the purpose of this study is to investigate the expression and correlations of Frat1 with clinic-pathologic parameters and prognosis in lung cancer.Method Immunohistochemistry was performed on 100 cases of NSCLC with complete follow-up records.The correlations between expressions of Frat1 and clinic-pathological characteristics and prognosis were analyzed.Results Frat1 was not detected in normal bronchial and alveolar epithelium,while it was positively expressed in 63(63.00%) of 100 NSCLC cases.The expression level of Frat1 was positively related to tumor differentiation,TNM stage and lymph node metastasis(0.05).The Kaplan-Meier survival analysis showed that survival time was significantly shorter in Frat1 positive expression cases than in Frat1 negative expression cases(0.01).Conclusion Overexpression of Frat1 in NSCLC is associated with malignant phenotype and poor prognosis,down-regulation of Frat1 expression can restrain the invasive ability of lung cancer cells.
出处 《解剖科学进展》 CAS 2012年第3期265-268,271,共5页 Progress of Anatomical Sciences
基金 国家自然科学基金资助项目(No.81071905 No.30870977)
关键词 Frat1 WNT信号通路 非小细胞肺癌 免疫组化 frequently rearranged in advanced T-cell lymphomas Wnt signal pathway non-small cell lung cancer immunohistochemistry
  • 相关文献

参考文献26

  • 1Haeseleer F, Pollet JF, Bollen A, et al. Molecular cloning and sequencing of the attachment site and integrase gene of the temperate mycobacteriophage FRATI[J]. Nucleic Acids Res, 1992, 20: 1420.
  • 2Jonkers J, Korswagen HC, Acton D, et al. Activation of a novel proto- oncogene, Fratl, contributes to progression of mouse T-celllymphomas[J]. Embo J, 1997, 16: 441-450.
  • 3Yost C, Farr GH, Pierce SB, et al. GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis[J]. Ce11,1998, 93: 1031-1041.
  • 4Hedgepeth CM, Deardorff MA, Rankin K, et al. Regulation of glycogen synthase kinase 3beta and downstream Wnt signaling by axin[J]. Mol Cell Biol, 1999, 19: 7147-7157.
  • 5Jonkers J, Weening J J, van der Valk M, et al. Overexpression of Fratl in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Fra! 1 in lymphoma progression[J]. Oncogene, 1999, 18: 5982-5990.
  • 6Thomas GM, Frame S, Goedert M, et al. A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphory- lation of axin and beta-catenin[J]. FEBS Lett, 1999, 458:247-251.
  • 7Bax B, Carter PS, Lewis C, et al. The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta- catenin phosphorylation[J]. Structure, 2001, 9:1143-1152.
  • 8Culbert AA, Brown MJ, Frame S, et al. GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity[J]. FEBS Lett, 2001, 507: 288-294.
  • 9Killick R, Pollard CC, Asuni AA, et al. Presenilin 1 independently regulates beta-catenin stability and transcriptional activity[J]. J Biol Chem, 2001,276: 48554-48561.
  • 10Saitoh T, Katoh M. FRAT1 and FRAT2, clustered in human chromosome 10q24.1 region, are up-regulated in gastric cancer[J]. IntJ Oncol, 2001, 19: 311-315.

二级参考文献5

  • 1左连富,齐风英,刘江惠,郭建文.乳腺癌P53基因蛋白的表达与临床预后的关系[J].癌症,1995,14(4):252-255. 被引量:13
  • 2Uicc TNM. Callification of malignant tumour [M]. 5ed New York:Wiley-Liss, 1997,93~97.
  • 3Fujino M, Dosaka-Akita H, Harada M, et al. Prognostic significance of p53 and p21 expression in non-small cell lung cancer [J].Cancer, 1995,76(12) :2457 ~2463.
  • 4Fu XL, Zhu XZ, Shi DR, et al. Study of prognostic predictors for non-small cell lung cancer [J]. Lung Cancer, 1999,23(2): 143 ~152.
  • 5Lee JS, Yoon A, Kalapurakal SK, et al. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor [J]. J Clin Oncol, 1995,13(8):1893 ~1903.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部